Unknown PHASE1 INTERVENTIONAL 1-arm NCT04049929

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Interventions YY-20394

Updated 5 times since 2019 Last updated: Aug 7, 2019 Started: Aug 31, 2019 Primary completion: Oct 31, 2020 Completion: Oct 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumor, this trial is ongoing. The trial is conducted by Shanghai YingLi Pharmaceutical Co. Ltd. and has accumulated 5 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1
Sep 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai YingLi Pharmaceutical Co. Ltd.

Data source: Shanghai YingLi Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China